PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas

Inclusion Criteria:

* Pts with MG histologically confirmed at diagnosis, who were treated previously with conventional external beam radiation \& with or without chemotherapy, \& have stable disease, recurrence or relapse at the time of enrollment.
* Age \> or = to 18 years.
* Patients who have had previous surgical resection(s) are eligible.
* Interval of at least 3 weeks between prior surgical resection, 2 weeks between prior radiotherapy, or 4 weeks between prior chemotherapy, unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy.
* Karnofsky performance score \> or = to 60%.
* Adequate hematologic, renal \& liver function as demonstrated by lab values performed within 14 days, inclusive, prior to administration of chemotherapy:
* ANC \> or = to 1500/mm3
* Platelet count \> or = to 100,000/mm3
* Hemoglobin \> or = to 10 gm/dL
* BUN and serum creatinine \<1.5 times upper limit of lab normal
* Total serum bilirubin \<1.5 times upper limit of lab normal
* SGOT \<2.5 times upper limit of lab normal
* Patients must have recovered from any effects of major surgery.
* Patients must have life expectancy of greater than 12 weeks.
* Patients or legal guardian must give written, informed consent.

Exclusion Criteria:

* Patients requiring immediate radiation therapy.
* Patients who have not recovered from surgery.
* Patients who are not neurologically stable for 2 weeks prior to study entry.
* Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics.
* Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction).
* Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
* Known HIV positivity or AIDS-related illness.
* Pregnant or nursing women.
* Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to administration of study drug and be practicing medically approved contraceptive precautions.
* Men who are not advised to use an effective method of contraception.
* Patients taking immuno-suppressive agents other than prescribed corticosteroids.
* Patients previously treated with farnesyl transferase inhibitors.
* Patients with significant QTc prolongation (\>500 msec)as evaluated by an EKG.
* Patients having presented prior disease progression on TEMODAR.
* Patients having presented any grade 4 hematologic toxicity or grade 3 or 4 non-hematologic toxicity on TEMODAR in the past.